Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419045 | 1.00 | TLR8 (0.55) | TLR8TLR7NPSR1LMNAGAA | |
| SCHEMBL6416413 | 0.93 | TLR8 (0.56) | TLR8TLR7NPSR1 | |
| SCHEMBL12495463 | 0.91 | TLR8 (0.47) | TLR8TLR7LMNAGAAMAPT | |
| SCHEMBL3830025 | 0.89 | TLR8 (0.49) | TLR8TLR7NPSR1LMNAGAA | |
| SCHEMBL8515321 | 0.87 | NPSR1 (0.47) | TLR8TLR7NPSR1 | |
| SCHEMBL12496379 | 0.83 | TLR8 (0.47) | TLR8TLR7NPSR1 | |
| SCHEMBL9203920 | 0.81 | NPSR1 (0.49) | TLR8TLR7NPSR1 | |
| SCHEMBL9499496 | 0.79 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL3458103 | 0.79 | NPSR1 (0.50) | TLR8TLR7NPSR1MAPTL3MBTL1 | |
| SCHEMBL6419615 | 0.79 | TLR8 (0.55) | TLR8TLR7GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176744-A1 | Use of 4-Aminopyrimidines for Controlling Harmful Fungi, Novel 4-Aminopyrimidines, Processes for Their Preparation and Compositions Comprising Them | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1858327-A1 | USE OF 4-AMINOPYRIMIDINES FOR THE PREVENTION OF FUNGAL PESTS NOVEL 4-AMINOPYRIMIDINES METHOD FOR PRODUCTION THEREOF AND AGENTS COMPRISING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094994-A1 | USE OF 4-AMINOPYRIMIDINES FOR THE PREVENTION OF FUNGAL PESTS NOVEL 4-AMINOPYRIMIDINES METHOD FOR PRODUCTION THEREOF AND AGENTS COMPRISING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176744-A1 | Use of 4-Aminopyrimidines for Controlling Harmful Fungi, Novel 4-Aminopyrimidines, Processes for Their Preparation and Compositions Comprising Them | RRM2B, CBR3, RRM2 | TLR8 3417/4885TLR7 3670/4885NPSR1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.